# EDGAR Filing Document

**Accession Number:** 0002096997
**File Stem:** 0001193125-26-159585
**Filing Date:** 2026-4
**Character Count:** 13332
**Document Hash:** 4449c953d0e2cc4412ef40c7268adbec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-159585.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001193125-26-159585

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**EFFECTIVENESS DATE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kailera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002096997
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295114
- **FILM NUMBER:** 26868907

**BUSINESS ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 508-440-9475

**MAIL ADDRESS:**
- **STREET 1:** 180 THIRD AVENUE
- **STREET 2:** 4TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**As filed with the Securities and Exchange Commission on April 16, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-1** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Kailera Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **99-3088927** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Primary Standard Industrial**<br> **Classification Code Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**180 Third Avenue, 4th Floor** 

**Waltham, MA 02451** 

**(781) 317-0290** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Ronald C. Renaud, Jr.** 

**Chief Executive Officer** 

**180 Third Avenue, 4th Floor** 

**Waltham, MA 02451** 

**(781) 317-0290** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | | |
|:---|:---|:---|
| **Peter N. Handrinos**<br> **Wesley C. Holmes**<br> **Elisabeth M. Martin**<br> **Latham & Watkins LLP**<br> **200 Clarendon Street**<br> **Boston, MA 02116**<br> **(617) 948-6000** | **Scott Akamine**<br> **John Mei**<br> **Kailera Therapeutics, Inc.**<br> **180 Third Avenue, 4th Floor**<br> **Waltham, MA 02451**<br> **(781) 317-0290** | **Siavosh Salimi**<br> **Ryan S. Brewer**<br> **Paul Hastings LLP**<br> **The MetLife Building**<br> **200 Park Avenue**<br> **New York, NY 10166**<br> **(212) 318-6000** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this Registration Statement is declared effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-294690)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definition of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Large accelerated filer |  | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer |  | ☒ | Smaller reporting company | ☒ |
|  |  |  | Emerging growth company | ☒ |
| <br> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒ | <br> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒ | <br> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒ | <br> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒ | <br> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒ |

---

**The Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE** 

This Registration Statement on Form S-1 (this "Registration Statement") is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the sole purpose of increasing the aggregate number of shares of common stock offered by Kailera Therapeutics, Inc. (the "Registrant") by 6,588,541 shares, 859,375 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Filing Fee Table (Exhibit 107) filed as an exhibit to the Registration Statement on Form S-1, as amended (File No. 333-294690) (the "Prior Registration Statement"). The information set forth in the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference in this filing.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

------

**Exhibit Index** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description of Exhibit** |
| 5.1 | [Opinion of Latham & Watkins LLP (incorporated by reference to Exhibit 5.1 filed with the Prior Registration Statement on April 13, 2026)](http://www.sec.gov/Archives/edgar/data/2096997/000119312526151904/d113532dex51.htm) |
| 23.1 | [Consent of Ernst & Young LLP, independent registered public accounting firm](d110326dex231.htm) |
| 23.2 | [Consent of Latham & Watkins LLP (included in Exhibit 5.1)](http://www.sec.gov/Archives/edgar/data/2096997/000119312526151904/d113532dex51.htm) |
| 24.1 | [Power of Attorney (included on the signature page of the Prior Registration Statement filed on March 27, 2026)](http://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm#sig) |
| 107 | [Filing Fee Table](d110326dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on this 16th day of April, 2026.

---

| | |
|:---|:---|
| **Kailera Therapeutics, Inc.** | **Kailera Therapeutics, Inc.** |
| By: | /s/ Ronald C. Renaud, Jr. |
|  | Ronald C. Renaud, Jr. |
|  | President and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Ronald C. Renaud, Jr. | President, Chief Executive Officer and Director<br> (principal executive officer) | April 16, 2026 |
| Ronald C. Renaud, Jr. | President, Chief Executive Officer and Director<br> (principal executive officer) | April 16, 2026 |
| /s/ Douglas Pagán | Chief Financial Officer<br> (principal financial and accounting officer) | April 16, 2026 |
| Douglas Pagán | Chief Financial Officer<br> (principal financial and accounting officer) | April 16, 2026 |
| \* | Director | April 16, 2026 |
| Frank Clyburn, Jr. | Director | April 16, 2026 |
| \* | Director | April 16, 2026 |
| Christopher Hite | Director | April 16, 2026 |
| \* | Director | April 16, 2026 |
| Andrew Kaplan | Director | April 16, 2026 |
| \* | Director | April 16, 2026 |
| Adam Koppel, M.D., Ph.D. | Director | April 16, 2026 |
| \* | Director | April 16, 2026 |
| Yuting (Shelley) Liu, Ph.D. |  |  |
| \* | Director | April 16, 2026 |
| Martin Mackay, Ph.D. |  |  |
| \* | Director | April 16, 2026 |
| John F. Milligan, Ph.D. |  |  |

---

---

| | |
|:---|:---|
| \*By: | /s/ Ronald C. Renaud, Jr. |
|  | Ronald C. Renaud, Jr. |
|  | Attorney-in-fact |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement on Form S-1 filed pursuant to Rule 462(b) of the Securities Act of 1933 of the reference to our firm under the caption "Experts" and to the incorporation by reference of our report dated February 11, 2026, with respect to the consolidated financial statements of Kailera Therapeutics, Inc. included in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-294690) and related Prospectus of Kailera Therapeutics, Inc. for the registration of its common stock.

/s/ Ernst & Young LLP

Boston, Massachusetts

April 16, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Kailera Therapeutics, Inc.**  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.00001 per share | 457(a) | 6588541 | $16.00 | $105416656.00 | 0.0001381 | $14558.04 |
| Fees Previously Paid |  |  |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $105416656.00  |  | $14558.04  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $14558.04  |

---

 **Offering Note** <br>

<sup>1</sup> The registrant previously registered securities with a proposed maximum aggregate offering price not to exceed $613,333,344 on a Registration Statement on Form S-1 (File No. 333-294690), which was declared effective by the Securities and Exchange Commission on April 16, 2026. In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, an additional amount of securities having a proposed maximum aggregate offering price of $105,416,656.00 is hereby registered, which includes the shares of common stock that the underwriters have the option to purchase.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---